Last reviewed · How we verify
ABBV-668
ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK).
ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.
At a glance
| Generic name | ABBV-668 |
|---|---|
| Sponsor | AbbVie |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting BTK, ABBV-668 disrupts B-cell receptor signaling, which is crucial for the survival and function of malignant B cells. This mechanism of action is particularly relevant in the treatment of certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Approved indications
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory marginal zone lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis (PHASE2)
- A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-668 CI brief — competitive landscape report
- ABBV-668 updates RSS · CI watch RSS
- AbbVie portfolio CI